Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study
Introduction MATCH was a randomized, double-blind, placebo-controlled study enrolling Japanese and Korean men aged ≥ 40 years who still had overactive bladder (OAB) symptoms while receiving tamsulosin. After a 4-week single-blind screening period in which patients received placebo and tamsulosin, patients were randomized to mirabegron 50 mg + tamsulosin or placebo + tamsulosin for 12 weeks (n = 568). This post hoc analysis investigated the proportion of treatment responders for each treatment group and for subgroups stratified by age based on voiding diaries and patient-reported outcomes (PROs). Methods Responders were defined as those achieving normalization or clinically meaningful improvements in efficacy, or clinically important differences in PROs [≥ 10-point improvement in OAB questionnaire (OAB-q) symptom bother or total health-related quality of life (HRQoL) subscales at end of treatment (EoT; minimally important difference [MID]) or OAB symptom score (OABSS) total score decreased by ≥ 3 points at EoT [minimally clinically important change (MCIC)]]. Results At EoT, micturition frequency normalization was achieved by 30.7% of tamsulosin + mirabegron patients and 18.6% of tamsulosin + placebo patients. Normalization of urgency and incontinence was 19.1% and 60.7% for tamsulosin + mirabegron and 18.2% and 60.0% for tamsulosin + placebo. Normalization of OAB symptoms based on OABSS was 17.1% for tamsulosin + mirabegron and 14.5% for tamsulosin + placebo. Higher proportions of patients in the mirabegron add-on group versus the placebo group reported clinically meaningful improvements in micturitions, urgency, and incontinence and in MCIC for OABSS and MID for the OAB-q subscales. Double- and triple-responder findings were as predicted by the results of single-responder analyses. These results were mirrored in the age groups using cut-offs of 65 and 75 years. Conclusion Mirabegron therapy added on to tamsulosin resulted in a higher frequency of responders in terms of normalization (e.g., micturition frequency normalization), clinically meaningful improvements in efficacy (e.g., ≥ 50% decrease in urgency), and minimally important changes in PROs (e.g., MCIC in OABSS). Trial Registration ClinicalTrials.gov identifier, NCT02656173..
Graphical Plain Language Summary.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
---|---|
Enthalten in: |
Advances in therapy - 38(2020), 1 vom: 27. Nov., Seite 739-757 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kakizaki, Hidehiro [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Add-on |
---|
doi: |
10.1007/s12325-020-01517-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR042978661 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR042978661 | ||
003 | DE-627 | ||
005 | 20230519223616.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210203s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-020-01517-5 |2 doi | |
035 | |a (DE-627)SPR042978661 | ||
035 | |a (DE-599)SPRs12325-020-01517-5-e | ||
035 | |a (SPR)s12325-020-01517-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Kakizaki, Hidehiro |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction MATCH was a randomized, double-blind, placebo-controlled study enrolling Japanese and Korean men aged ≥ 40 years who still had overactive bladder (OAB) symptoms while receiving tamsulosin. After a 4-week single-blind screening period in which patients received placebo and tamsulosin, patients were randomized to mirabegron 50 mg + tamsulosin or placebo + tamsulosin for 12 weeks (n = 568). This post hoc analysis investigated the proportion of treatment responders for each treatment group and for subgroups stratified by age based on voiding diaries and patient-reported outcomes (PROs). Methods Responders were defined as those achieving normalization or clinically meaningful improvements in efficacy, or clinically important differences in PROs [≥ 10-point improvement in OAB questionnaire (OAB-q) symptom bother or total health-related quality of life (HRQoL) subscales at end of treatment (EoT; minimally important difference [MID]) or OAB symptom score (OABSS) total score decreased by ≥ 3 points at EoT [minimally clinically important change (MCIC)]]. Results At EoT, micturition frequency normalization was achieved by 30.7% of tamsulosin + mirabegron patients and 18.6% of tamsulosin + placebo patients. Normalization of urgency and incontinence was 19.1% and 60.7% for tamsulosin + mirabegron and 18.2% and 60.0% for tamsulosin + placebo. Normalization of OAB symptoms based on OABSS was 17.1% for tamsulosin + mirabegron and 14.5% for tamsulosin + placebo. Higher proportions of patients in the mirabegron add-on group versus the placebo group reported clinically meaningful improvements in micturitions, urgency, and incontinence and in MCIC for OABSS and MID for the OAB-q subscales. Double- and triple-responder findings were as predicted by the results of single-responder analyses. These results were mirrored in the age groups using cut-offs of 65 and 75 years. Conclusion Mirabegron therapy added on to tamsulosin resulted in a higher frequency of responders in terms of normalization (e.g., micturition frequency normalization), clinically meaningful improvements in efficacy (e.g., ≥ 50% decrease in urgency), and minimally important changes in PROs (e.g., MCIC in OABSS). Trial Registration ClinicalTrials.gov identifier, NCT02656173. | ||
520 | |a Graphical Plain Language Summary | ||
650 | 4 | |a Add-on |7 (dpeaa)DE-He213 | |
650 | 4 | |a Mirabegron |7 (dpeaa)DE-He213 | |
650 | 4 | |a Overactive bladder |7 (dpeaa)DE-He213 | |
650 | 4 | |a Responder |7 (dpeaa)DE-He213 | |
650 | 4 | |a Tamsulosin |7 (dpeaa)DE-He213 | |
650 | 4 | |a Urology |7 (dpeaa)DE-He213 | |
700 | 1 | |a Lee, Kyu-Sung |e verfasserin |4 aut | |
700 | 1 | |a Katou, Daisuke |e verfasserin |4 aut | |
700 | 1 | |a Yamamoto, Osamu |e verfasserin |4 aut | |
700 | 1 | |a Sumarsono, Budiwan |e verfasserin |4 aut | |
700 | 1 | |a Uno, Satoshi |e verfasserin |4 aut | |
700 | 1 | |a Yamaguchi, Osamu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 38(2020), 1 vom: 27. Nov., Seite 739-757 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:38 |g year:2020 |g number:1 |g day:27 |g month:11 |g pages:739-757 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-020-01517-5 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 38 |j 2020 |e 1 |b 27 |c 11 |h 739-757 |